Efficacy

Conclusions

• Campath is effective in a population of patients for whom no approved therapies are available (CAM211)

  • Objective response 33.3% (95% CI [24, 44])
  • Median survival 16 months (95% CI [11.8, --])

• Supportive studies consistent

  • Objective response (28.1%, 33.3%)
  • Median survival (25.9 months, 27.5 months)

• Meaningful clinical benefit

Previous slide

Next slide

Back to first slide

View graphic version